- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 11, 2026 · gurufocus.com
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CLEVELAND, May 01, 2026 (GLOBE NEWSWIRE) -- Abeona Thera
- Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
May 11, 2026 · globenewswire.com
CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced activation of the Children's Hospital of Philadelphia (CHOP) as the sixth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. “Activation of CHOP is a significant step forward for the Recessive dystrophic epidermolysis bullosa (RDEB) community expanding access to ZEVASKYN in the east coast,” said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona.
- ABEONA THERAPEUTICS® ANNOUNCES ACTIVATION OF CHILDREN'S HOSPITAL OF PHILADELPHIA AS A NEW QUALIFIED TREATMENT CENTER FOR ZEVASKYN®
May 11, 2026
CLEVELAND, MAY 11, 2026 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING GENETIC MEDICINES FOR SERIOUS DISEASES WITH HIGH UNMET NEED, TODAY ANNOUNCED ACTIVATION OF THE CHILDREN'S HOSPITAL OF PHILADELPHIA (CHOP) AS THE SIXTH QUALIFIED TREATMENT CENTER (QTC) FOR THE ADMINISTRATION OF ZEVASKYN (PRADEMAGENE ZAMIKERACEL) GENE-MODIFIED CELLULAR SHEETS. “ACTIVATION OF CHOP IS A SIGNIFICANT STEP FORWARD FOR THE RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB) COMMUNITY EXPANDING ACCESS TO ZEVASKYN IN THE EAST COAST,” SAID DR. MADHAV VASANTHAVADA, CHIEF COMMERCIAL OFFICER OF ABEONA.
- High Insider Ownership Boosts These Growth Stocks In May 2026
May 8, 2026
The United States market has experienced a robust performance, climbing 3.2% in the last week and rising by 31% over the past year, with earnings projected to grow by 16% annually in the coming years. In this thriving environment, growth companies with high insider ownership are particularly noteworthy as they often signal strong confidence from those closest to the business, aligning their interests with shareholders and potentially enhancing long-term value creation.
Top 10 Growth Companies With High Insider Ownership In The United States
Name Insider Ownership Earnings Growth Uxin (UXIN) 35.7% 74.1% Upstart Holdings (UPST) 12.8% 58.2% Precigen (PGEN) 11.9% 68.4% Karman Holdings (KRMN) 17% 53.2% Hesai Group (HSAI) 17.5% 27.1% Clene (CLNN) 10.9% 62.2% Caledonia Mining (CMCL) 14.1% 29.6% Astera Labs (ALAB) 10.8% 31.8% AppLovin (APP) 27.4% 21.4% Abeona Therapeutics (ABEO) 16.8% 29.8%
Click here to see the full list of 191 stocks from our Fast Growing US Companies With High Insider Ownership screener.
Let's explore several standout options from the results in the screener.
AlTi Global
Simply Wall St Growth Rating: ★★★★☆☆
Overview: AlTi Global, Inc. is a company that offers wealth and asset management services across various countries including France, Hong Kong, Italy, Portugal, Singapore, Switzerland, the United Kingdom, and the United States with a market cap of $566.53 million.
Operations: The company's revenue is primarily derived from its Wealth & Capital Solutions segment, which generated $254.96 million.
Insider Ownership: 34.3%
Earnings Growth Forecast: 130.9% p.a.
AlTi Global is experiencing significant insider interest, with former CEO Michael Tiedemann holding a 9.8% stake and exploring a buyout to take the company private. Despite recent leadership changes, including Nancy Curtin as interim CEO, AlTi's revenue rose to US$254.96 million in 2025 from US$198.39 million in 2024. The company's earnings are forecasted to grow substantially by over 130% annually, outpacing the broader US market growth expectations of 11.4%.
Click to explore a detailed breakdown of our findings in AlTi Global's earnings growth report. In light of our recent valuation report, it seems possible that AlTi Global is trading beyond its estimated value.ALTI Earnings and Revenue Growth as at May 2026
PDF Solutions
Simply Wall St Growth Rating: ★★★★☆☆
Overview: PDF Solutions, Inc. offers proprietary software, intellectual property for integrated circuit designs, measurement hardware tools, methodologies, and professional services globally with a market cap of $1.92 billion.
Operations: The company's revenue is primarily derived from its software and programming segment, which generated $219.02 million.
Story Continues
Insider Ownership: 11%
Earnings Growth Forecast: 83.4% p.a.
PDF Solutions is poised for growth with expected earnings expansion of 83.36% annually, surpassing the US market's average. Despite a recent net loss of US$0.64 million for 2025, revenue grew to US$219.02 million from US$179.47 million in 2024, and it is forecasted to continue growing at 17.6% per year. The company has not engaged in significant insider trading recently but maintains a focus on achieving profitability within three years.
Get an in-depth perspective on PDF Solutions' performance by reading our analyst estimates report here. Our valuation report unveils the possibility PDF Solutions' shares may be trading at a premium.PDFS Ownership Breakdown as at May 2026
TIC Solutions
Simply Wall St Growth Rating: ★★★★☆☆
Overview: TIC Solutions, Inc. offers essential asset integrity services across North America and has a market cap of $2.29 billion.
Operations: Revenue Segments (in millions of $): null
Insider Ownership: 11.3%
Earnings Growth Forecast: 112.2% p.a.
TIC Solutions is navigating a growth trajectory with earnings expected to expand by 112.23% annually, outpacing the US market's average. Despite recent losses, including a first-quarter net loss of US$41.55 million, revenue surged to US$488.03 million from US$234.22 million year-over-year. The company trades at 73% below estimated fair value and plans to repurchase up to $200 million in shares, indicating potential undervaluation and confidence in future profitability within three years under new CEO Benjamin Heraud's leadership.
Delve into the full analysis future growth report here for a deeper understanding of TIC Solutions. According our valuation report, there's an indication that TIC Solutions' share price might be on the cheaper side.TIC Earnings and Revenue Growth as at May 2026
Make It Happen
Delve into our full catalog of 191 Fast Growing US Companies With High Insider Ownership here. Seeking Other Investments? Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include ALTIPDFS and TIC.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- May 2026's Top Growth Companies With Insider Influence
May 8, 2026
Over the last 7 days, the United States market has risen by 3.2%, contributing to a remarkable 31% increase over the past year, with earnings projected to grow by 16% annually. In such a robust environment, growth companies with high insider ownership often stand out as they can benefit from strong internal alignment and commitment to long-term success.
Top 10 Growth Companies With High Insider Ownership In The United States
Name Insider Ownership Earnings Growth Uxin (UXIN) 35.7% 74.1% Upstart Holdings (UPST) 12.8% 58.2% SharonAI Holdings (SHAZ) 29.9% 97.4% Precigen (PGEN) 11.9% 68.4% Karman Holdings (KRMN) 17% 53.2% Clene (CLNN) 10.9% 62.2% Caledonia Mining (CMCL) 14.1% 29.6% Astera Labs (ALAB) 10.8% 31.8% AppLovin (APP) 27.4% 21.4% Abeona Therapeutics (ABEO) 16.8% 29.8%
Click here to see the full list of 191 stocks from our Fast Growing US Companies With High Insider Ownership screener.
We'll examine a selection from our screener results.
Webull
Simply Wall St Growth Rating: ★★★★★☆
Overview: Webull Corporation operates as a digital investment platform with a market cap of approximately $3.98 billion.
Operations: The company generates revenue primarily from its brokerage services, amounting to $564.33 million.
Insider Ownership: 18.4%
Webull Corporation, with significant insider ownership, is poised for growth as it implements a $100 million share repurchase program funded by existing cash flow. The company has shown strong revenue growth of 45.1% over the past year and is forecasted to grow revenue at 21.6% annually, outpacing the market average. Recent initiatives such as zero-commission trading in Canada and enhanced digital asset surveillance reflect its commitment to expanding user engagement and maintaining robust market integrity.
Click here and access our complete growth analysis report to understand the dynamics of Webull. Our expertly prepared valuation report Webull implies its share price may be too high.BULL Ownership Breakdown as at May 2026
Ethos Technologies
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Ethos Technologies Inc. offers third-party administrator services for insurance policies in the United States and has a market cap of $1.45 billion.
Operations: Ethos Technologies Inc. generates its revenue primarily from providing third-party administrator services for insurance policies in the United States.
Insider Ownership: 22.2%
Ethos Technologies, characterized by high insider ownership, is leveraging its innovative digital platform to drive growth. Despite a recent net loss of US$166.39 million in Q1 2026, revenue surged to US$193.1 million from US$94.89 million year-over-year. The company launched a ChatGPT app for life insurance estimates and expanded partnerships with Liberty Mutual and Banner Life Insurance, enhancing accessibility and affordability in the market while forecasting significant annual profit growth over the next three years.
Story Continues
Take a closer look at Ethos Technologies' potential here in our earnings growth report. Insights from our recent valuation report point to the potential overvaluation of Ethos Technologies shares in the market.LIFE Ownership Breakdown as at May 2026
Circle Internet Group
Simply Wall St Growth Rating: ★★★★★☆
Overview: Circle Internet Group, Inc. operates as a platform, network, and market infrastructure for stablecoin and blockchain applications with a market cap of $29.54 billion.
Operations: The company's revenue is primarily derived from its data processing segment, which generated $2.75 billion.
Insider Ownership: 11.6%
Circle Internet Group, with substantial insider ownership, is poised for growth despite recent volatility. The company forecasts a 46.34% annual earnings growth and aims to become profitable within three years. Recent collaborations with Mesh and Kyriba enhance its USDC settlement capabilities, streamlining cross-border transactions. However, legal challenges persist due to a major hack involving its stablecoin infrastructure. Despite these hurdles, Circle continues to expand its global financial network and digital asset solutions.
Get an in-depth perspective on Circle Internet Group's performance by reading our analyst estimates report here. According our valuation report, there's an indication that Circle Internet Group's share price might be on the expensive side.CRCL Ownership Breakdown as at May 2026
Taking Advantage
Click through to start exploring the rest of the 188 Fast Growing US Companies With High Insider Ownership now. Ready To Venture Into Other Investment Styles? Uncover the next big thing with financially sound penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include BULLLIFE and CRCL.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Abeona Therapeutics® Announces Date of First Quarter Financial Results
May 4, 2026 · globenewswire.com
CLEVELAND, May 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, May 13, 2026 at 8:30 a.m. ET to discuss its financial results for the first quarter of 2026 and corporate progress.
- ABEONA THERAPEUTICS® ANNOUNCES DATE OF FIRST QUARTER FINANCIAL RESULTS
May 4, 2026
CLEVELAND, MAY 04, 2026 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO) TODAY ANNOUNCED IT WILL HOST A CONFERENCE CALL ON WEDNESDAY, MAY 13, 2026 AT 8:30 A.M. ET TO DISCUSS ITS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026 AND CORPORATE PROGRESS.
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026
CLEVELAND, May 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
On April 30, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to eight individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 112,621 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the grant date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to successfully commercialize and market ZEVASKYN, including manufacturing sufficient batches of ZEVASKYN to meet demand; the therapeutic potential of ZEVASKYN; whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections by the FDA or other regulatory agencies, including those relating to preclinical programs and to the cGMP manufacturing of ZEVASKYN; the ability to achieve or obtain necessary regulatory approvals for our pre-clinical programs; the impact of any changes in the financial markets and global economic conditions, including those resulting from changes to U.S. trade policy, such as current or future tariffs; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Contacts:
Investor and Media
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com
Investor
Lee M. Stern
Meru Advisors
lstern@meruadvisors.com
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026 · globenewswire.com
CLEVELAND, May 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- ABEONA THERAPEUTICS® ANNOUNCES NEW EMPLOYEE INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
May 1, 2026
CLEVELAND, MAY 01, 2026 (GLOBE NEWSWIRE) -- ABEONA THERAPEUTICS INC. (NASDAQ: ABEO) TODAY ANNOUNCED IT HAS GRANTED EQUITY AWARDS TO NEW NON-EXECUTIVE EMPLOYEES WHO JOINED THE COMPANY. THE EQUITY AWARDS WERE APPROVED IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).
